GlassScriptPhysician profile
Leabeth M Pack
NPI 1154747889
$5,788.84
in general payments reported to CMS, 2019-2025
33 companies · $1,563 in 2025
The $1,563 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $719 · 2022: $1,254 · 2023: $798 · 2024: $1,454 · 2025: $1,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,815.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,549.70 | 2021-2025 | |
| Novo Nordisk INC | $821.85 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $467.20 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $447.24 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Corcept Therapeutics | $306.10 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $207.35 | 2022-2023 | Xarelto |
| Exact Sciences Corporation | $185.90 | 2023-2025 | Cologuard Collection Kit |
| Antares Pharma, INC. | $174.80 | 2022-2025 | Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.48 | 2021-2025 | Xifaxan, Trulance |
| Inspire Medical Systems, INC. | $174.37 | 2024-2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $153.49 | 2021 | |
| Shield Therapeutics INC | $148.57 | 2024-2025 | |
| Glaxosmithkline, LLC. | $114.38 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Xeris Pharmaceuticals, INC. | $112.59 | 2021-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $99.61 | 2021-2024 | Veozah |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $88.03 | 2021-2023 | |
| Abbott Laboratories | $70.30 | 2022-2024 | Freestyle Libre 2 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.68 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $47.56 | 2024-2025 | Gemtesa |
| Pfizer INC. | $46.97 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.88 | 2024-2025 | Jardiance |
| Hologic Sales and Service, LLC | $43.11 | 2022-2024 | Aptima |
| Kowa Pharmaceuticals America, INC. | $42.52 | 2021-2022 | |
| Tolmar, INC. | $29.76 | 2024-2025 | Jatenzo |
| Merck Sharp & Dohme LLC | $26.03 | 2022 | |
| Nevro Corp. | $25.08 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.38 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19.50 | 2021 | |
| Insulet Corporation | $18.49 | 2022 | |
| Halozyme INC | $18.07 | 2023 | |
| Allergan, INC. | $16.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.63 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leabeth Pack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.